文献速递肺外科

实性或微乳头型成分对切除的IB期肺腺癌患者的预后意义及辅助化疗的生存获益

Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-11-07

本研究纳入1131例按第8版TNM分期为病理IB期的肺腺癌患者,按实性/微乳头型成分比例分为SMPN组719例、SMPM组272例和SMPP组140例。SMPM和SMPP是疾病特异性生存和复发无生存的不良预后因素;SMPP患者接受辅助化疗后肺癌特异性死亡和复发的累积发生率显著降低。

要点

  • 实性/微乳头型成分即使不占主导也与较差预后相关。
  • SMPP患者接受辅助化疗与肺癌特异性死亡和复发风险降低相关。
  • 按实性/微乳头型比例分组可识别辅助化疗潜在获益人群。

核心结论

  • 实性/微乳头型成分与较差预后相关,即使未占主导。
  • 辅助化疗在IB期肺腺癌SMPP亚组中带来生存获益。

研究设计与样本

  • 研究纳入1131例按第8版TNM分期为病理IB期、接受肺叶切除或肺段切除的肺腺癌患者。
  • 按实性/微乳头型成分比例分为SMPN组(n=719)、SMPM组(n=272)和SMPP组(n=140)。
  • 采用倾向性评分匹配分析以减少选择偏倚。

主要发现

  • SMPM组肺癌特异性死亡累积发生率显著高于SMPN组(P=.000),复发累积发生率也显著高于SMPN组(P=.000)。
  • SMPP组肺癌特异性死亡累积发生率显著高于SMPM组(P=.000),复发累积发生率也显著高于SMPM组(P=.000)。
  • 多因素分析显示SMPM是疾病特异性生存的不良预后因素(HR 1.86,95%CI 1.12-3.09),SMPP也是(HR 4.56,95%CI 2.69-7.71)。
  • 多因素分析显示SMPM是复发无生存的不良预后因素(HR 1.64,95%CI 1.20-2.24),SMPP也是(HR 2.43,95%CI 1.64-3.60)。
  • SMPP组接受辅助化疗者肺癌特异性死亡累积发生率更低(HR 0.46,95%CI 0.22-0.93,P=.031),复发累积发生率也更低(HR 0.48,95%CI 0.26-0.88,P=.017)。

关键数值与推荐

  • SMPN组中位生存49.7个月(IQR 35.1-67.0个月)。
  • SMPM组中位生存38.8个月(IQR 26.6-51.5个月)。
  • SMPP组中位生存39.6个月(IQR 26.8-52.5个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the prognostic significance and beneficiaries of adjuvant chemotherapy (ACT) in various histological patterns of stage IB lung adenocarcinoma according to the 8th tumor-node-metastasis (TNM) classification. METHODS: A total of 1131 patients with pathological stage IB lung adenocarcinoma according to the 8th TNM classification who underwent lobectomy or segmentectomy were enrolled in this study. Based on the proportion of solid/micropapillary components, the patients were classified into 3 groups: solid/micropapillary-negative (SMPN) (n = 719; median survival, 49.7 months; interquartile range [IQR]. 35.1-67.0 months), solid/micropapillary-minor (SMPM; >5% but not predominant) (n = 272; median survival, 38.8 months; IQR, 26.6-51.5 months) and solid/micropapillary-predominant (SMPP; >5% and the most dominant) (n = 140; median survival, 39.6 months; IQR, 26.8-52.5 months). The predictors of disease-specific survival and recurrence-free survival were investigated. To reduce selection bias, propensity score-matching analysis was implemented before survival data were compared. RESULTS: Our data show significant differences in survival rates based on the proportion of solid/micropapillary patterns. The SMPM group had significantly higher cumulative incidences of lung cancer-specific death (P = .000) and recurrence (P = .000) compared with the SMPN group, so did the SMPP group when compared with SMPM patients (P = .000 for both). Multivariate analysis showed that the SMPM and SMPP patterns were poor prognostic factors for disease-specific survival (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.12-3.09 and HR, 4.56; 95% CI, 2.69-7.71, respectively) and recurrence-free survival (HR, 1.64; 95% CI, 1.20-2.24 and HR, 2.43; 95% CI, 1.64-3.60, respectively), as were older age, male sex, smoking history, larger tumor size, necrosis, and abnormal pulmonary function. Survival analysis stratified by histological pattern showed that patients with the SMPP pattern who received ACT had obviously lower cumulative incidences of lung cancer-specific death (HR, 0.46; 95% CI, 0.22-0.93; P = .031) and recurrence (HR, 0.48; 95% CI, 0.26-0.88; P = .017). CONCLUSIONS: Solid/micropapillary patterns were associated with poor prognosis, even if they were not predominant. ACT contributed to survival benefits in the SMPP subgroup of patients with stage IB lung adenocarcinoma.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Qian F, Yang W, Wang R, et al. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017. PMID: 29223834. doi:10.1016/j.jtcvs.2017.09.143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。